Compare SNGX & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | AMBO |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | United States | United States |
| Employees | N/A | 160 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 4.2M |
| IPO Year | 2006 | 2010 |
| Metric | SNGX | AMBO |
|---|---|---|
| Price | $0.33 | $1.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 103.2K | 1.4K |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.03 | ★ 337.04 |
| EPS | N/A | ★ 0.00 |
| Revenue | $119,371.00 | ★ $9,469,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $328.57 |
| Revenue Growth | N/A | ★ 0.82 |
| 52 Week Low | $0.32 | $1.35 |
| 52 Week High | $3.39 | $5.25 |
| Indicator | SNGX | AMBO |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 37.44 |
| Support Level | $0.32 | $1.47 |
| Resistance Level | $0.82 | $2.25 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 10.57 | 31.33 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.